Statins protect against arrhythmogenic calcium alternans in the post–myocardial infarction diabetic heart: Pleiotropy on steroids

  • Richard L. Verrier
    Address reprint requests and correspondence: Dr Richard L. Verrier, Beth Israel Deaconess Medical Center, Division of Cardiovascular Medicine, 99 Brookline Avenue, RN-301, Boston MA 02215-3908.
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    Search for articles by this author
      Statins' broad spectrum of beneficial cardiovascular effects, including reduction in coronary artery disease deaths and myocardial infarctions (MIs), often evokes the term pleiotropy. This therapeutic accolade appears well deserved, given the multimodal actions by which this class of lipid-lowering agents exerts its salutary influences on coronary, cerebral, and other vasculatures. The overall reduction in ischemic burden owing to amelioration of plaque progression results from diverse effects on endothelial function, signaling pathways of inflammation, endothelial nitric oxide synthesis, platelet activation, angiotensin II receptor regulation, and plaque stabilization, to name a few.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Shanes J.G.
        • Minadeo K.N.
        • Moret A.
        • Groner M.
        • Tabaie S.A.
        Statin therapy in heart failure: prognostic effects and potential mechanisms.
        Am Heart J. 2007; 154: 617-623
        • Das M.
        • Zipes D.P.
        Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention.
        J Cardiovasc Pharmacol. 2010; 55: 438-449
        • Vyas A.K.
        • Guo H.
        • Moss A.J.
        • Olshansky B.
        • McNitt S.A.
        • Hall W.J.
        • Zareba W.
        • Steinberg J.S.
        • Fischer A.
        • Ruskin J.
        • Andrews M.L.
        • MADIT-II Research Group
        Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.
        J Am Coll Cardiol. 2006; 47: 769-773
        • Goldberger J.J.
        • Subacius H.
        • Schaechter A.
        • Howard A.
        • Berger R.
        • Shalaby A.
        • Levine J.
        • Kadish A.H.
        • DEFINITE Investigators
        Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy.
        J Am Coll Cardiol. 2006; 48: 1228-1233
        • Jin H.
        • Welzig C.M.
        • Aronovitz M.
        • Noubary F.
        • Blanton R.
        • Wang B.
        • Rajab M.
        • Albano A.
        • Link M.S.
        • Noujaim S.F.
        • Park H.-J.
        • Galper J.B.
        QRS/T-wave and calcium alternans in a type 1 diabetic mouse model for spontaneous post myocardial infarction ventricular tachycardia: a mechanism for the antiarrhythmic effect of statins.
        Heart Rhythm. 2017; 14: 1406-1416
        • Kayo T.
        • Koizumi A.
        Mapping of murine diabetogenic gene Mody on chromosome 7 at D7Mit258 and its involvement in pancreatic islet and β cell development during the perinatal period.
        J Clin Invest. 1998; 101: 2112-2118
        • Verrier R.L.
        • Klingenheben T.
        • Malik M.
        • El-Sherif N.
        • Exner D.
        • Hohnloser S.
        • Ikeda T.
        • Martinez J.P.
        • Narayan S.
        • Nieminen T.
        • Rosenbaum D.S.
        Microvolt T-wave alternans: physiologic basis, methods of measurement, and clinical utility. Consensus guideline by the International Society for Holter and Noninvasive Electrocardiology.
        J Am Coll Cardiol. 2011; 44: 1309-1324
        • Weiss J.N.
        • Nivala M.
        • Garfinkel A.
        • Qu Z.
        Alternans and arrhythmias: from cell to heart.
        Circ Res. 2011; 108: 98-112
        • Díaz M.E.
        • O'Neill S.C.
        • Eisner D.A.
        Sarcoplasmic reticulum calcium content fluctuation is the key to cardiac alternans.
        Circ Res. 2004; 94: 650-656
        • Laurita K.R.
        • Rosenbaum D.S.
        Cellular mechanisms of arrhythmogenic cardiac alternans.
        Prog Biophys Mol Biol. 2008; 97: 332-347
        • Qu Z.
        • Nivala M.
        • Weiss J.N.
        Calcium alternans in cardiac myocytes: order from disorder.
        J Mol Cell Cardiol. 2013; 58: 100-109
        • Choi K.M.
        • Zhong Y.
        • Hoit B.D.
        • Grupp I.L.
        • Hahn H.
        • Dilly K.W.
        • Guatimosim S.
        • Lederer W.J.
        • Matlib M.A.
        Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in Type 1 diabetic rats.
        Am J Physiol Heart Circ Physiol. 2002; 283: H1398-H1408
        • Verrier R.L.
        • Ikeda T.
        Ambulatory ECG-based T-wave alternans monitoring for risk assessment and guiding medical therapy: mechanisms and clinical applications.
        Prog Cardiovasc Dis. 2013; 56: 172-185
        • Mozaffarian D.
        • Benjamin E.J.
        • Go A.S.
        • et al.
        Heart disease and stroke statistics: 2016 update: a report from the American Heart Association.
        Circulation. 2016; 133: e38-e360

      Linked Article